Vericiguat Market

Vericiguat Market Size, Share & Industry Analysis, By Manufacturer Type (In-house API manufacturers, and Third-party/Outsourced manufacturers), By Application (Chronic Heart Failure (CHF) (Primary segment), Cardiovascular Disease Research, and Others), By End-User (Pharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), and Academic & Research Institutes), Forecast 2025–2035

Vericiguat API market is projected to grow at a CAGR of 6.8% between 2025 and 2035. The market growth is driven by the rising global burden of chronic heart failure (CHF) and the increasing adoption of novel cardiovascular therapies. Vericiguat, a soluble guanylate cyclase (sGC) stimulator, has gained recognition as a breakthrough treatment for patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).

Among various segments, the pharmaceutical-grade API for chronic heart failure holds the largest share due to the approved use of Vericiguat under brand names such as Verquvo in the United States and Europe. Pharmaceutical companies and contract manufacturing organizations (CMOs) dominate the end-user segment, as they focus on the commercial-scale production of high-purity APIs for branded formulations. The demand is also increasing among contract research organizations (CROs) and academic institutions for clinical trial supply and research purposes.

Geographically, North America, particularly the US, represents the largest market for vericiguat API, owing to early FDA approval, high disease prevalence, and the strong presence of major pharmaceutical players. Europe follows closely, with Germany and the UK being key markets due to Bayer’s strong footprint. The Asia-Pacific region, especially India and China, is emerging as a significant contributor due to the presence of cost-efficient API manufacturing hubs and growing cardiovascular disease prevalence.

Prominent players in the market include Bayer AG, Merck & Co., Inc., and several leading API manufacturers such as Dr. Reddy’s Laboratories, Lupin Limited, and Zhejiang Hisun Pharmaceutical. These companies are focusing on strategic collaborations, API supply agreements, and innovation in production technologies to maintain competitiveness.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

  1. Introduction
  • Overview of Vericiguat
  • Key Applications & Industry Use Cases
  • Market Scope & Study Objectives
  1. Market Overview
  • Global Market Size & Growth Trends (Historical & Forecast)
  • Market Value & Revenue Analysis
  • Demand-Supply Dynamics
  1. Segmental Outlook
  • By Manufacturer Type
    • In-house API manufacturers
    • Third-party/Outsourced manufacturers
  • By Application
    • Chronic Heart Failure (CHF)
    • Cardiovascular Disease Research
    • Others
  • By End-User
    • Pharmaceutical Companies
    • Contract Manufacturing Organizations (CMOs)
    • Contract Research Organizations (CROs)
    • Academic & Research Institutes
  • By Manufacturer Type
    • In-house API manufacturers
    • Third-party/Outsourced manufacturers
  1. Price Analysis
  • Current Price Trends (Per kg & Per Ton)
  • Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
  • Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)
  1. Production & Supply Volume
  • Global Production Capacity & Key Manufacturers
  • Production Process & Technological Developments
  • Raw Material Analysis
  1. Trade Analysis (Import & Export)
  • Major Exporting & Importing Countries
  • Trade Volume & Value Statistics
  • Impact of Trade Regulations & Policies
  1. Regional Analysis
  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
  • Rest of the World (Latin America, Middle East, and Africa)
  1. Competitive Landscape
  • Top Global Manufacturers & Market Share
  • Company Profiles & Key Developments
  • Mergers, Acquisitions & Investments
  1. Regulatory & Compliance Factors
  • FDA, REACH, and Other Regulatory Frameworks
  • Environmental & Safety Considerations
  • Emerging Policies Impacting Market Growth
  1. Conclusion & Strategic Recommendations
  • Key Takeaways for Stakeholders
  • Market Entry Strategies
1. What is Vericiguat?
Vericiguat is an active pharmaceutical ingredient (API) used to treat symptomatic chronic heart failure. It works as a soluble guanylate cyclase (sGC) stimulator, helping improve blood vessel function and reduce heart strain.
2. What is the market growth of Vericiguat API?
Vericiguat API market is projected to grow at a CAGR of 6.8% between 2025 and 2035, driven by rising heart failure cases and adoption of advanced cardiovascular therapies.
3. What are the drivers of the Vericiguat API market?
Key drivers include increasing prevalence of heart failure, demand for targeted therapies, supportive regulatory approvals, and expanding pharmaceutical manufacturing capacity.
4. Who are the key players operating in the Vericiguat API market?
Major players include Bayer AG, Merck & Co., Dr. Reddy’s Laboratories, Lupin Limited, and Zhejiang Hisun Pharmaceutical, with strategic focus on supply partnerships and production scale-up.
5. Which region would exhibit the fastest growth in the Vericiguat API market?
Asia-Pacific, led by India and China, is expected to witness the fastest growth due to cost-efficient API manufacturing, rising cardiovascular disease burden, and growing export activities.
$1800/- Single User License
$3600/- Multi User License

How can we help you?

Reach out to discuss how our team can help your business achieve real results.